First Subcutaneous Prophylaxis for Hemophilia A and B With Inhibitors Approved by FDA
The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with inhibitors by preventing or reducing bleeding episodes in adults and children 12 years and older.
Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma
Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
The Role of Geriatric Assessment Tools in Enhancing Oncology Care: ASH 2024
A pair of studies from The American Society of Hematology (ASH) Annual Meeting & Exposition provides insights into the prognostic utility of geriatric assessment tools and their role in tailoring therapy to improve patient outcomes.
Year-End Spending Bill to Feature Reforms for Pharmacy Benefit Managers and Telehealth Access
The health care provisions include key reforms targeting pharmacy benefit managers, extensions of Medicare telehealth flexibilities, and measures aimed at combating the opioid crisis and preparing for future pandemics.
Health Equity & Access Weekly Roundup: December 15, 2024
Recent analyses spotlight inequities in health care, from the financial burdens faced by employees at small firms due to higher insurance costs to disparities in data and ovarian cancer survival among racial and ethnic groups.
Confronting Systemic Racial Inequities in Health Care Data Must Start With Employers
Robin Glasgow, MBA, executive leadership advisor of Spencer Stuart, discusses the critical role of data in health care, emphasizing the need to address pervasive biases in data collection and algorithms.
Rare Blood Disease Innovations Address Unmet Needs, According to ASH Data
Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, with key research presented on immune thrombocytopenia, hemophilia, and multiple myeloma.
New Data Reinforce Iptacopan's Role in Transforming PNH Care With Hemoglobin, QOL Gains
Promising topline results from a phase 3B study show the efficacy and quality of life (QOL) improvements of iptacopan (Fabhalta) as a twice-daily oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who transitioned from anti-C5 therapies.
US ADHD Stimulant Shortage Highlights Growing Challenges in Adult Treatment
While name brands like Adderall and Vyvanse may have been recently removed from the FDA Drug Shortage Database, it's unclear if it'll last; meanwhile, many generic forms of attention-deficit/hyperactivity disorder (ADHD) medication are still in short supply.
Progression-Free Survival in Relapsed Multiple Myeloma Extended With Ixazomib, Data Show
Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies in improving outcomes, particularly in regions with limited access to chimeric antigen receptor T cells and bispecific antibodies.
Health Equity & Access Weekly Roundup: November 23, 2024
Americans are underinsured, even with employer-based health plans; a thorough critique of the lack of representation among Black patients in clinical trials showcases a persistent theme; systemic barriers in cardiology, breast cancer, and patent systems are examined.
Despite Record ACA Enrollment, Report Reveals Underinsured Americans Are in Crisis
Despite significant progress in expanding health insurance coverage since the Affordable Care Act (ACA) was enacted, millions of Americans still face critical gaps in access to and affordability of health care.
New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease
Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.